NM26-2198

Table of contents

• What is NM26-2198?
• How does NM26-2198 work?
• Which conditions is it studied for?
• How is NM26-2198 given?
• What do the clinical trials show?
• What side effects are known?

What is NM26-2198?

NM26-2198, also known as JNJ-95475939, is an investigational bispecific, tetravalent antibody. It is a protein-based substance developed for the treatment of moderate to severe atopic dermatitis, a chronic inflammatory skin condition.^[3] The substance has no marketing authorisation in the product records, meaning it is still being studied in clinical trials and is not available as a licensed medicine.^[1] The authorisation holder listed in the trial record is Janssen-Cilag International N.V.^[1]

How does NM26-2198 work?

NM26-2198 is designed as a bispecific antibody, meaning it can bind to two different targets at the same time. According to a review of emerging therapies, it targets both inflammatory and pruritogenic (itch-related) pathways involved in atopic dermatitis.^[3] Most currently approved biologic treatments for atopic dermatitis target only one molecule, whereas multi-specific antibodies such as NM26-2198 are intended to block several pathways at once. This approach is being explored because many patients treated with single-target biologics still do not achieve clear or almost clear skin.^[2] The review lists NM26-2198 among a growing group of bispecific and trispecific antibodies being developed for atopic dermatitis.^[2]

Which conditions is it studied for?

• Moderate to severe atopic dermatitis — a long-lasting inflammatory skin disease that causes intense itching and skin lesions. The Phase 2b trial enrolled participants with this severity of disease.^[1]

How is NM26-2198 given?

NM26-2198 is formulated as a solution for injection and is given by subcutaneous use, meaning it is injected under the skin.^[1] The trial compared NM26-2198 with dupilumab (Dupixent), which was also given subcutaneously, and with a placebo version of NM26-2198.^[1]

What do the clinical trials show?

One Phase 2b trial of NM26-2198 is registered. It was a multicentre, randomised, double-blind study that included 240 participants with moderate to severe atopic dermatitis.^[1] The trial was designed to evaluate the efficacy and safety of different doses of NM26-2198 compared with placebo and with dupilumab.^[1] The primary outcome was EASI 75 at Week 12, which measures the proportion of participants achieving at least a 75% improvement in the Eczema Area and Severity Index (EASI) from the start of the study.^[1] The trial is listed as completed, but the registry records do not include the results.^[1]

What side effects are known?

The available sources do not provide specific information on side effects observed with NM26-2198. No safety data from the completed trial or from other publications are described in the records provided.